TITLE

Reasons for Declining to Enroll in a Phase I and II HIV Vaccine Trial after Randomization among Eligible Volunteers in Dar es Salaam, Tanzania

AUTHOR(S)
Tarimo, Edith A. M.; Thorson, Anna; Kohi, Thecla W.; Bakari, Muhammad; Mhalu, Fred; Kulane, Asli
PUB. DATE
February 2011
SOURCE
PLoS ONE;2011, Vol. 6 Issue 2, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Recruitment, enrollment and retention of volunteers in an HIV vaccine trial is important in the efforts to ultimately develop a vaccine that can prevent new HIV infections. Following recruitment, some randomized individuals decline to be enrolled in an HIV vaccine trial. The reasons for such a decision are not well known. This article describes why individuals who were randomized in a phase I and II HIV vaccine trial in Dar es Salaam, Tanzania declined to be enrolled. Methods: Face-to-face interviews were conducted with 14 individuals (7 men and 7 women). Repeated readings of the 14 interview transcripts to look for reasons for declining to enroll in the trial were performed. Data was analyzed using the content analysis approach. Results: Informants expressed fear of the outcome of an experimental HIV vaccine in their lives. Unlike women, some men were concerned over the effect of the vaccine on their reproduction intentions. Women were concerned about the unknown effects of the vaccine in their bodies. Also, to a large extent, informants faced resistance from significant others such as fiancées, parents, relatives, and friends. Women were influenced by their potential intimate sexual partners; men were forbidden by their parents, and mothers had the most influential opinion. Conclusions: Fear of the negative outcome of an experimental vaccine and resistance from significant others are the main reasons for declining to enroll in the HIV vaccine trial among eligible volunteers after randomization. The resistance from the significant others provides valuable guidance for designing future trials in Tanzania; for example, expanding the HIV vaccine trial education to the general population from the onset of the trial design.
ACCESSION #
73936995

 

Related Articles

  • Vaccination-Induced Noncytolytic Effects in the Acute Phase of SHIV Infection. Petravic, Janka; Davenport, Miles P. // PLoS ONE;2010, Vol. 5 Issue 11, p1 

    Many studies have shown that vaccines inducing CD8+ T cell responses can reduce viral loads and preserve CD4+ T cell numbers in monkey models of HIV infection. The mechanism of viral control by the vaccine-induced CD8+ T cells is usually assumed to be cytolysis of infected cells. However, in...

  • The Role of Race and Gender in T Cell Responses in Children Perinatally Infected with HIV-1. Kovacs, Andrea; Villacres, Maria C. // Journal of Infectious Diseases;11/15/2005, Vol. 192 Issue 10, p1683 

    Studies the role of race and gender in T cell responses in children perinatally infected with HIV-1. View that the understanding the immunologic mechanisms that can control the progression of HIV disease is paramount for the development of vaccines or of new strategies for immunotherapy; Finding...

  • Chemoprophylaxis of HIV Infection: Moving Forward with Caution. Grant, Robert M.; Wainberg, Mark A. // Journal of Infectious Diseases;10/1/2006, Vol. 194 Issue 7, p874 

    The article discusses the use of antiretroviral drugs in preexposure prophylaxis for HIV infection. A study suggested that tenofovir disoproxil fumarate may not be sufficient for the prevention of HIV infection when used as a single agent. Moreover, the predictive value of non-human primate...

  • The role played by alternative splicing in antigenic variability in human endo-parasites. Hull, Rodney; Dlamini, Zodwa // Parasites & Vectors;2014, Vol. 7 Issue 1, p1 

    Endo-parasites that affect humans include Plasmodium, the causative agent of malaria, which remains one of the leading causes of death in human beings. Despite decades of research, vaccines to this and other endo-parasites remain elusive. This is in part due to the hypervariability of the...

  • HIV Superinfection. Smith, Davey M.; Richman, Douglas D.; Little, Susan J. // Journal of Infectious Diseases;8/1/2005, Vol. 192 Issue 3, p438 

    Worldwide, 16 cases of HIV-1 superinfection in humans have been reported since 2002. Superinfection is defined as the reinfection of an individual who already has an established infection with a heterologous HIV strain. Controversy exists surrounding superinfection, because it has implications...

  • Reservoirs for HIV Infection and Their Persistence in the Face of Undetectable Viral Load. Sonza, Secondo; Crowe, Suzanne M. // AIDS Patient Care & STDs;Oct2001, Vol. 15 Issue 10, p511 

    Discusses the nature of cellular reservoirs and sanctuary tissue sites that enable the persistence of HIV infections. Benefits associated with the highly active antiretroviral therapy for HIV infections; Evidence of the existence of a long-lived, latently-infected cellular reservoir;...

  • Call for HIV-negative activists. Kennedy, Tom // Bay Area Reporter;3/23/2006, Vol. 36 Issue 12, p6 

    The article focuses on the HIV prevention tools in the U.S. Finding a safe and effective vaccine is the best long-term hope to stop the global spread of the disease. An example of a partially effective vaccine is the first polio vaccine introduced in the country. HIV medications holds several...

  • AIDS vaccine: new ideas from old approaches. Beale, A. J. // Journal of the Royal Society of Medicine;Jul2003, Vol. 96 Issue 7, p347 

    The article discusses the methods of immunization in monkeys for HIV infection prevention research in the U.S. It included the use of live attenuated vaccine, it gave protection for macaques against free and cell bound Simian immunodeficiency virus. The other approach is alloimmunization wherein...

  • Protective Efficacy of Centralized and Polyvalent Envelope Immunogens in an Attenuated Equine Lentivirus Vaccine. Craigo, Jodi K.; Ezzelarab, Corin; Cook, Sheila J.; Liu, Chong; Horohov, David; Issel, Charles J.; Montelaro, Ronald C. // PLoS Pathogens;Jan2015, Vol. 11 Issue 1, p1 

    Lentiviral Envelope (Env) antigenic variation and related immune evasion present major hurdles to effective vaccine development. Centralized Env immunogens that minimize the genetic distance between vaccine proteins and circulating viral isolates are an area of increasing study in HIV...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics